Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
ConditionAggressive NK Cell Leukemia
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorHiroshima University Hospital
About this trial
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
Eligibility criteria
Qualifiers
Patients diagnosed with ANKL (regardless of whether the disease is first or recurrent) based on diagnostic criteria developed with reference to the World Health Organization (WHO) 4th edition (2017) criteria.
Disqualifiers
Patients eligible to receive chemotherapy as treatment for ANKL
Trial design
Treatments tested in this trial
- PPMX-T003
Treatment groups
7 Participants
are divided into 1 treatment groupSponsors and collaborators
Hiroshima University Hospital
Lead sponsor
Kyoto University Hospital
Collaborator
Hokkaido University Hospital
Collaborator
Okayama University
Collaborator
Tokai University
Collaborator
Kyushu University
Collaborator
Tohoku University
Collaborator
Nagoya University
Collaborator
Komagome Hospital
Collaborator
Source ClinicalTrials.gov